BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

9697 related articles for article (PubMed ID: 12014625)

  • 1. Melanoma-inhibiting activity (MIA/CD-RAP) is expressed in a variety of malignant tumors of mainly neuroectodermal origin.
    Hau P; Apfel R; Wiese P; Tschertner I; Blesch A; Bogdahn U
    Anticancer Res; 2002; 22(2A):577-83. PubMed ID: 12014625
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mouse CD-RAP/MIA gene: structure, chromosomal localization, and expression in cartilage and chondrosarcoma.
    Bosserhoff AK; Kondo S; Moser M; Dietz UH; Copeland NG; Gilbert DJ; Jenkins NA; Buettner R; Sandell LJ
    Dev Dyn; 1997 Apr; 208(4):516-25. PubMed ID: 9097023
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Detection of melanoma cells in the blood of melanoma patients by melanoma-inhibitory activity (MIA) reverse transcription-PCR.
    Mühlbauer M; Langenbach N; Stolz W; Hein R; Landthaler M; Buettner R; Bosserhoff AK
    Clin Cancer Res; 1999 May; 5(5):1099-105. PubMed ID: 10353744
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Melanoma-inhibiting activity, a novel serum marker for progression of malignant melanoma.
    Bosserhoff AK; Kaufmann M; Kaluza B; Bartke I; Zirngibl H; Hein R; Stolz W; Buettner R
    Cancer Res; 1997 Aug; 57(15):3149-53. PubMed ID: 9242442
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In situ expression patterns of melanoma-inhibiting activity (MIA) in melanomas and breast cancers.
    Bosserhoff AK; Moser M; Hein R; Landthaler M; Buettner R
    J Pathol; 1999 Mar; 187(4):446-54. PubMed ID: 10398105
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression levels of melanoma inhibitory activity correlate with time to progression in patients with high-grade glioma.
    Hau P; Ruemmele P; Kunz-Schughart LA; Doerfelt A; Hirschmann B; Lohmeier A; Koch H; Mueller A; Bogdahn U; Bosserhoff AK
    Oncol Rep; 2004 Dec; 12(6):1355-64. PubMed ID: 15547763
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Melanoma-inhibiting activity (MIA) mRNA is not exclusively transcribed in melanoma cells: low levels of MIA mRNA are present in various cell types and in peripheral blood.
    de Vries TJ; Fourkour A; Punt CJ; Diepstra H; Ruiter DJ; van Muijen GN
    Br J Cancer; 1999 Nov; 81(6):1066-70. PubMed ID: 10576666
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cloning and characterization of the expression pattern of a novel splice product MIA (splice) of malignant melanoma-derived growth-inhibiting activity (MIA/CD-RAP) [corrected].
    Hau P; Wise P; Bosserhoff AK; Blesch A; Jachimczak P; Tschertner I; Bogdahn U; Apfel R
    J Invest Dermatol; 2002 Sep; 119(3):562-9. PubMed ID: 12230496
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MIA, a novel serum marker for progression of malignant melanoma.
    Bosserhoff AK; Lederer M; Kaufmann M; Hein R; Stolz W; Apfel R; Bogdahn U; Buettner R
    Anticancer Res; 1999; 19(4A):2691-3. PubMed ID: 10470221
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum cartilage-derived retinoic acid-sensitive protein (CD-RAP) levels in swarm rat chondrosarcoma.
    Yonekawa M; Kondo S; Sugiura H; Kobayashi K; Watanabe T; Kimata K; Sandell LJ; Iwata H
    J Orthop Res; 2002 Mar; 20(2):382-6. PubMed ID: 11918321
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of S100 protein and MIA protein as serum marker for malignant melanoma.
    Djukanovic D; Hofmann U; Sucker A; Rittgen W; Schadendorf D
    Anticancer Res; 2000; 20(3B):2203-7. PubMed ID: 10928178
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular characterization and chromosomal assignment of equine cartilage derived retinoic acid sensitive protein (CD-RAP)/melanoma inhibitory activity (MIA).
    Berg LC; Mata X; Thomsen PD
    Gene; 2008 Jan; 407(1-2):98-104. PubMed ID: 17977671
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Functional role of MIA in melanocytes and early development of melanoma.
    Poser I; Tatzel J; Kuphal S; Bosserhoff AK
    Oncogene; 2004 Aug; 23(36):6115-24. PubMed ID: 15208686
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of melanoma inhibitory activity and other differentially expressed messenger RNAs in human melanoma cell lines with different metastatic capacity by messenger RNA differential display.
    van Groningen JJ; Bloemers HP; Swart GW
    Cancer Res; 1995 Dec; 55(24):6237-43. PubMed ID: 8521420
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Decreased expression of both the low-density lipoprotein receptor-related protein/alpha(2)-macroglobulin receptor and its receptor-associated protein in late stages of cutaneous melanocytic tumor progression.
    de Vries TJ; Verheijen JH; de Bart AC; Weidle UH; Ruiter DJ; van Muijen GN
    Cancer Res; 1996 Mar; 56(6):1432-9. PubMed ID: 8640836
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Regulation of mesenchymal stem cell and chondrocyte differentiation by MIA.
    Tscheudschilsuren G; Bosserhoff AK; Schlegel J; Vollmer D; Anton A; Alt V; Schnettler R; Brandt J; Proetzel G
    Exp Cell Res; 2006 Jan; 312(1):63-72. PubMed ID: 16256983
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Overexpression of melanoma inhibitory activity (MIA) enhances extravasation and metastasis of A-mel 3 melanoma cells in vivo.
    Guba M; Bosserhoff AK; Steinbauer M; Abels C; Anthuber M; Buettner R; Jauch KW
    Br J Cancer; 2000 Nov; 83(9):1216-22. PubMed ID: 11027436
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Overexpression of Lerk-5/Eplg5 messenger RNA: a novel marker for increased tumorigenicity and metastatic potential in human malignant melanomas.
    Vogt T; Stolz W; Welsh J; Jung B; Kerbel RS; Kobayashi H; Landthaler M; McClelland M
    Clin Cancer Res; 1998 Mar; 4(3):791-7. PubMed ID: 9533549
    [TBL] [Abstract][Full Text] [Related]  

  • 19. p54nrb is a new regulator of progression of malignant melanoma.
    Schiffner S; Zimara N; Schmid R; Bosserhoff AK
    Carcinogenesis; 2011 Aug; 32(8):1176-82. PubMed ID: 21642354
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Elevated MIA serum levels are predictors of poor prognosis after surgical resection of metastatic malignant melanoma.
    Guba M; Steinbauer M; Ruhland V; Schütz A; Geissler EK; Anthuber M; Vogt T; Bosserhoff A; Jauch KW
    Oncol Rep; 2002; 9(5):981-4. PubMed ID: 12168059
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 485.